Rallybio Corporation (NASDAQ:RLYB) Receives Average Recommendation of “Reduce” from Brokerages

Shares of Rallybio Corporation (NASDAQ:RLYB) have earned an average recommendation of “Reduce” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company.

Several equities research analysts have issued reports on the company. Wall Street Zen upgraded Rallybio to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th.

Institutional Investors Weigh In On Rallybio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC lifted its holdings in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Renaissance Technologies LLC grew its stake in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares during the last quarter. Susquehanna International Group LLP increased its position in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the period. XTX Topco Ltd increased its position in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

Rallybio Price Performance

NASDAQ:RLYB opened at $8.43 on Friday. The firm has a 50-day moving average of $7.23 and a two-hundred day moving average of $5.87. The stock has a market cap of $44.59 million, a P/E ratio of -3.29 and a beta of -1.20. Rallybio has a 1-year low of $1.76 and a 1-year high of $11.49.

Rallybio (NASDAQ:RLYB) last announced its earnings results on Monday, March 16th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.01. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%. As a group, equities analysts expect that Rallybio will post -1.34 earnings per share for the current year.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.